The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Second-line treatment of advanced urothelial cancer with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35/09).
Guenter Niegisch
Consultant or Advisory Role - TopoTarget
Honoraria - Pierre Fabre Medicament
Margitta Retz
No relevant relationships to disclose
Mark K. Thalgott
No relevant relationships to disclose
Stefan Balabanov
No relevant relationships to disclose
Friedemann Honecker
No relevant relationships to disclose
Michael Stöckle
No relevant relationships to disclose
Carsten Henning Ohlmann
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Other Remuneration - Novartis
Martin Boegemann
No relevant relationships to disclose
Frank vom Dorp
No relevant relationships to disclose
Juergen Gschwend
No relevant relationships to disclose
Arndt Hartmann
No relevant relationships to disclose
Christian Ohmann
No relevant relationships to disclose
Peter Albers
Honoraria - Pierre Fabre Medicament
Research Funding - Novartis